GL Ventures, others back Exegenesis Bio and 13 more deal updates from Greater China

Hangzhou-based gene therapy company Exegenesis Bio Inc said on Tuesday that it has closed a Series B+ round funding raising “tens of millions of US dollars” led by LYFE Capital, a Chinese healthcare fund with $1.27 billion in assets under management.